Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > TIME has arrived on the Making of a Breast Cancer Vaccine

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 04, 2022 1:02pm

158 Views

Post# 35073640

RE:RE:TIME has arrived on the Making of a Breast Cancer Vaccine

Yesterday ABC news ran the following piece on the development of a potential breast cancer vaccine for HER2+ breast cancers which represent approximately 15% of all breast cancers.

In contrast ONCY's oncolytic virus/vaccine pelareorep has been trialed in HER2- breast cancer which represents approximately 80% of all breast cancers.

https://abcnews.go.com/GMA/Wellness/video/breast-cancer-vaccine-shows-promising-signs-preliminary-study-92655701

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project